Mazzotta C, et al. - Experts evaluated the 10-year follow-up effectiveness and safety of riboflavin ultraviolet A-induced cross-linking (CXL) in a population of pediatric patients aged 18 years and younger with progressive keratoconus (KC). Results showed the ability of CXL to slow down KC progression in pediatric patients, improving functional performance. With CXL-induced delay in corneal collagen turnover, and with spontaneous age-related KC stabilization long-term stability could be correlated. In the patients who were aged 15 years and younger at the time of inclusion in the treatment protocol, a 24% regression rate could be contemplated.